Cellosaurus logo
expasy logo

Cellosaurus A375-16R5-5 (CVCL_R752)

[Text version]
Cell line name A375-16R5-5
Synonyms 16R5-5
Accession CVCL_R752
Resource Identification Initiative To cite this cell line use: A375-16R5-5 (RRID:CVCL_R752)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI_75045; Dabrafenib (Tafinlar; GSK2118436).
Derived from site: In situ; Leg, skin; UBERON=UBERON_0001511.
Sequence variations
  • Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
Disease Amelanotic melanoma (NCIt: C3802)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_R745 (A375PF11)
Sex of cell Female
Age at sampling 54Y
Category Cancer cell line
Publications

PubMed=22389471; DOI=10.1158/1535-7163.MCT-11-0989
Greger J.G., Eastman S.D., Zhang V., Bleam M.R., Hughes A.M., Smitheman K.N., Dickerson S.H., Laquerre S.G., Liu L., Gilmer T.M.
Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
Mol. Cancer Ther. 11:909-920(2012)

Cross-references
Cell line databases/resources cancercelllines; CVCL_R752
Encyclopedic resources Wikidata; Q54606766
Polymorphism and mutation databases Cosmic; 1890491
Entry history
Entry creation05-Nov-2013
Last entry update19-Dec-2024
Version number18